Bengaluru: Eli Lilly and Company and Strides Arcolab inked a pact to increse delivery of cancer medicines in emerging markets. 'As a part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, based in Bangalore, India,' said Strides Arcolab in a company statement.
Agila will make cancer medicines and Lilly will market them in emerging geographies. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.
"Cancer medicines of the highest quality continue to be an unmet need in many markets around the world, said Jacques Tapiero, Lilly senior VP and president of its emerging markets division.
Arun Kumar, founder and group CEO of Strides Arcolab said, "We are delighted to partner with Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly's strong global
No comments:
Post a Comment